# Digital Flow Enhancement in Raynaud's Phenomenon With an sGC (Soluble Guanylate Cyclase) Stimulator

> **NCT01926847** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 23 (actual)

## Conditions studied

- Raynaud Disease

## Interventions

- **DRUG:** Riociguat (Adempas, BAY63-2521)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01926847
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2014-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01926847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01926847, "Digital Flow Enhancement in Raynaud's Phenomenon With an sGC (Soluble Guanylate Cyclase) Stimulator". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01926847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*